By Gary M. White, MD
The BRAF mutation inhibitor, vemurafenib, is approved for the treatment of adults with BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Various identifiable patterns of skin toxicity occur including maculopapular eruption, keratosis pilaris-like eruption, multiple milia, vasculitis and panniculitis, and SCC/KA and verrucous lesions.
- Topical 5-fluorouracil (for 7 weeks) has been used successfully in treating vemurafenib-induced SCC [BJD 2015;172;1135].
Reported Cutaneous Side Effects
- Maculopapular eruption
- DRESS/AGEP overlap [JEADV 2016;30;178]
- Keratosis pilaris-like eruption
- Multiple milia
- Verrucous lesions
- Panniculitis in children [PD 2017;34;337].
Multiple milia JAAD Oct 2013
KA induced by vemurafenib. British Journal of Dermatology 2015;172: 540–542
Homepage | FAQs | Contact Dr. White
It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.